GBP3 Inhibitors

GBP3 inhibitors in this context are primarily chemicals that indirectly affect the function of Guanylate Binding Protein 3 by influencing associated signaling pathways or cellular processes. Given GBP3's role in immune response modulation, particularly in reaction to interferon-gamma (IFN-γ), most of the listed inhibitors target pathways that are upstream or downstream of IFN-γ signaling.

The Janus kinase (JAK) inhibitors, such as Tofacitinib, Ruxolitinib, and Baricitinib, play a crucial role in this context. These inhibitors target the JAK-STAT pathway, a critical signaling mechanism in response to cytokines like IFN-γ. By inhibiting JAKs, these drugs potentially modulate the activity of downstream proteins, including GBP3, which are involved in the cellular response to IFN-γ. This modulation is particularly relevant in diseases where cytokine signaling is dysregulated. In addition to JAK inhibitors, the list includes drugs targeting interleukin receptors, such as Sarilumab, Siltuximab, Anakinra, and Tocilizumab. These drugs are designed to interfere with interleukin signaling pathways, particularly those involving IL-6 and IL-1, which are integral to immune response regulation. Their influence on GBP3 activity, while indirect, is rooted in the broad network of cytokine signaling in which GBP3 is a participant.